Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B8705eb9dff9e07295bd6b15655e542ab> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B8705eb9dff9e07295bd6b15655e542ab NCIT_P378 "NCI" @default.
- B8705eb9dff9e07295bd6b15655e542ab type Axiom @default.
- B8705eb9dff9e07295bd6b15655e542ab annotatedProperty IAO_0000115 @default.
- B8705eb9dff9e07295bd6b15655e542ab annotatedSource NCIT_C105853 @default.
- B8705eb9dff9e07295bd6b15655e542ab annotatedTarget "The dimesylate salt form of LY2228820, a tri-substituted imidazole derivative and orally available, p38 mitogen-activated protein kinase (MAPK) inhibitor with potential anti-inflammatory and antineoplastic activities. Upon administration, ralimetinib inhibits the activity of p38, particularly the alpha and beta isoforms, thereby inhibiting MAPKAPK2 phosphorylation and preventing p38 MAPK-mediated signaling. This may inhibit the production of a variety of cytokines involved in inflammation, cellular proliferation and angiogenesis such as tumor necrosis factor alpha (TNFa), interleukin (IL)-1, -6 and -8, vascular endothelial growth factor, and macrophage inflammatory protein-1 alpha. Ultimately this induces apoptosis and reduces tumor cell proliferation. In addition, inhibition of the p38 MAPK pathway by LY2228820 increases the antineoplastic activity of certain chemotherapeutic agents. p38 MAPK, a serine/threonine protein kinase that is often upregulated in cancer cells, plays a crucial role in tumor cell proliferation, angiogenesis and metastasis." @default.